Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established cirrhosis complicated by hepatic encephalopathy~* For the purposes of this study a patient will be considered to have cirrhosis if they fulfil two out of the three diagnostic criteria of confirmatory liver histology, biochemistry and/or radiologic findings consistent with cirrhosis/portal hypertension, and~* are presenting with chronic persistent overt hepatic encephalopathy (≥ grade 1) or with ≥2 episodes of overt hepatic encephalopathy in the previous 6 months.~Exclusion Criteria:~* Age ≤18 or ≥75.~* Evidence of disseminated malignancy.~* Known coeliac or inflammatory bowel disease.~* Evidence of intestinal failure, intestinal obstruction and / or previous bowel resection.~* Pre-existing immunosuppressive states including HIV infection and chronic granulomatous diseases.~* Anti-inflammatory drug use e.g non-steroidals and immunomodulatory drug use e.g. prednisolone and azathioprine.~* Known hypersensitivity to rifaximin or rifamycin-derivatives~* Already receiving concomitant oral or parenteral antibiotic therapy e.g norfloxacin.~* Infection with clostridium difficile or stool testing positive for clostridium difficile toxin in the previous 3 months.~* Pregnancy or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin-α (Type: ACTIVE_COMPARATOR): Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets - 550mg twice daily for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).